z-logo
open-access-imgOpen Access
Insulin resistance, oxidative stress, hypertension, and leukocyte telomere length in men from the Framingham Heart Study
Author(s) -
Demissie S.,
Levy D.,
Benjamin E. J.,
Cupples L. A.,
Gardner J. P.,
Herbert A.,
Kimura M.,
Larson M. G.,
Meigs J. B.,
Keaney J. F.,
Aviv A.
Publication year - 2006
Publication title -
aging cell
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.103
H-Index - 140
eISSN - 1474-9726
pISSN - 1474-9718
DOI - 10.1111/j.1474-9726.2006.00224.x
Subject(s) - insulin resistance , telomere , medicine , biology , endocrinology , oxidative stress , framingham heart study , insulin , offspring , framingham risk score , genetics , disease , gene , pregnancy
Summary Insulin resistance and oxidative stress are associated with accelerated telomere attrition in leukocytes. Both are also implicated in the biology of aging and in aging‐related disorders, including hypertension. We explored the relations of leukocyte telomere length, expressed by terminal restriction fragment (TRF) length, with insulin resistance, oxidative stress and hypertension. We measured leukocyte TRF length in 327 Caucasian men with a mean age of 62.2 years (range 40–89 years) from the Offspring cohort of the Framingham Heart Study. TRF length was inversely correlated with age ( r  = –0.41, P  < 0.0001) and age‐adjusted TRF length was inversely correlated with the Homeostatic Model Assessment of Insulin Resistance (HOMA‐IR) ( r  =–0.16, P  = 0.007) and urinary 8‐epi‐PGF 2α ( r  = –0.16, P  = 0.005) – an index of systemic oxidative stress. Compared with their normotensive peers, hypertensive subjects exhibited shorter age‐adjusted TRF length (hypertensives = 5.93 ± 0.042 kb, normotensives = 6.07 ± 0.040 kb, P  = 0.025). Collectively, these observations suggest that hypertension, increased insulin resistance and oxidative stress are associated with shorter leukocyte telomere length and that shorter leukocyte telomere length in hypertensives is largely due to insulin resistance.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here